Pneumococcal disease is an infection caused by the Streptococcus pneumoniae bacteria, which especially affects infants and children below 5 years of age.
The major factors that contribute to the growth of the pneumococcal polysaccharide vaccine market include increasing prevalence of pneumonia globally, improving healthcare infrastructure, rise in government focus on immunization programs for pneumonia, and development of quality vaccines such as PPSV23. 

The global Pneumococcal Polysaccharide Vaccine market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Pneumococcal Polysaccharide Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pneumococcal Polysaccharide Vaccine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pneumococcal Polysaccharide Vaccine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pneumococcal Polysaccharide Vaccine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck & Co., Inc.
Pfizer Inc.
Glaxosmithkline Plc.
Sanofi Pasteur
China National Biotec Group
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Single Dose Vial
Pre-Filled Syringe

Segment by Application
Children (2-10 Age)
Adult (10-64 Age)
Geriatric (More Than 65 Age)